STOCK TITAN

Roivant to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Roivant Sciences (Nasdaq: ROIV) announced CEO Matt Gline will present at two conferences: the B. Riley Securities Virtual Oncology Conference on January 27, 2022, at 12:30 p.m. ET, and the SVB Leerink Global Healthcare Conference on February 17, 2022, at 1:00 p.m. ET. Live webcasts will be available on the Roivant investor website, with archived recordings accessible for 30 days. Roivant aims to enhance healthcare delivery and develop transformative medicines through its innovative platform.

Positive
  • None.
Negative
  • None.

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at two upcoming conferences:

  • B. Riley Securities Virtual Oncology Conference on Thursday, January 27, 2022 at 12:30 p.m. ET
  • SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 p.m. ET

A live webcast of each presentation will be available under “Events & Presentations” on the Investors section of the Roivant website at https://investor.roivant.com/news-events/events and an archived recording of the presentations will be available for 30 days.

About Roivant Sciences
Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch 'Vants' – nimble and focused biopharmaceutical and health technology companies. For more information, please visit www.roivant.com.

Roivant Sciences Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are usually identified by the use of words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


FAQ

When is Matt Gline presenting at the B. Riley Securities Virtual Oncology Conference?

Matt Gline will present at the B. Riley Securities Virtual Oncology Conference on January 27, 2022, at 12:30 p.m. ET.

What is the date of the SVB Leerink Global Healthcare Conference?

The SVB Leerink Global Healthcare Conference is scheduled for February 17, 2022, at 1:00 p.m. ET.

Where can I watch the Roivant Sciences presentations?

You can watch the presentations on the Roivant investor website under 'Events & Presentations'.

How long will the archived recordings of Roivant's presentations be available?

The archived recordings of Roivant's presentations will be available for 30 days.

What is Roivant Sciences' mission?

Roivant Sciences aims to improve healthcare delivery by treating inefficiencies as opportunities and developing transformative medicines.

What is the stock symbol for Roivant Sciences?

Roivant Sciences trades under the stock symbols ROIV and ROIVW.

Roivant Sciences Ltd. Common Shares

NASDAQ:ROIV

ROIV Rankings

ROIV Latest News

ROIV Stock Data

8.59B
739.52M
29.09%
74.67%
6.79%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HAMILTON HM11